Antibody (1)
Launched (1)
Mouse (1)
- (1)
Unconjugated (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
GHL-MY2111 | HEK293 | Monoclonal Anti-VZV gH & gL Antibody, Human IgG1 (4F12) (MALS verified) |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| XCUR-17 | XCUR-17 | Phase 1 Clinical | Exicure Inc | Psoriasis | Details |
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Brodalumab | IL-17R mAb; MEDI-6365; KHK-4827; AMG-827 | Approved | Amgen Inc | Siliq, Lumicef, Kyntheum, 立美芙 | Japan | Psoriasis; Arthritis, Psoriatic | Kyowa Kirin Co Ltd | 2016-07-04 | Non-radiographic axial spondyloarthritis; Arthritis, Rheumatoid; Spondylitis, Ankylosing; Scleroderma, Systemic; Psoriasis; Asthma; Arthritis, Psoriatic; Hidradenitis Suppurativa; Crohn Disease; Plaque psoriasis | Details |




